Skip to main content
Fig. 2 | Journal of Neuroinflammation

Fig. 2

From: Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis

Fig. 2

Immature, transitional and regulatory B cells are the first B cells to repopulate after SID and EID. A UMAP plot displays pre-gated CD19 + cells from the blood of CG, SID and EID patients. Colours correspond to PARC-guided clustering. B Percentage of each annotated B cell population out of the total CD45+ cells from CG, SID and EID patients. Each data point corresponds to each individual, columns and error bars show mean ± SEM. P-values indicate the statistical differences after a GLM model with age, sex and type of MS as covariates. C Proportional stacked bar graph showing the percentage of each annotated B cell cluster out of the CD19+ cells from CG, SID and EID patients. D Heatmap indicates the median scaled intensity of the corresponding markers across B cell subpopulations. The size of the circles (right) represents the value of the p-value and the colour represents the direction of change between the different experimental groups. *adjusted p-value < 0.05, **adjusted p-value < 0.01, ***adjusted p-value < 0.001, ****adjusted p-value < 0.0001. GLM multivariate general linear model, CG control group, SID standard interval dosing, EID extended interval dosing

Back to article page